
Publication|Articles|February 21, 2025
Peers & Perspectives in Oncology
- February 2025
- Pages: 76
Roundtable Roundup: Bladder Cancer
Author(s)Targeted Oncology Staff
Fact checked by: Dylann Bailey
In separate, live virtual events, David H. Aggen, MD, PhD; and Matthew R. Zibelman, MD, discussed the case of a patient with urothelial carcinoma and potential treatment options.
Advertisement
CASE SUMMARY
A man aged 74 years presents to his primary care physician reporting intermittent episodes of painless macrohematuria.
History
- Stage 3a chronic kidney disease; type 2 diabetes
- New York Heart Association heart failure grade 2
- Medications: empagliflozin once daily; enalapril once daily
- Mild chronic obstructive pulmonary disease
- Tobacco history: current smoker, 20 pack-years
- Retired textile chemist
Focused Physical Exam
- ECOG performance status: 1
- Pulmonary: diminished lung sounds, inspiratory rhonchi, expiratory wheezing on auscultation
Evaluation by Urologic Oncologist
- History of renal insufficiency: cisplatin-ineligible
- Arterial portography MRI and magnetic resonance urography:
- Nodular, 6-cm lesion within the left, posterior bladder wall invasive into inner half of muscularis propria
- No renal parenchymal masses
- Enlarged single, regional, obturator node, measuring 8 mm
- No evidence of lymph node involvement or hepatic metastasis
- Chest CT without metastasis
- White light cystoscopy and barbotage detected single, penetrating lesion along right lateral bladder wall
- Bladder wash samples and multiple tissue specimens obtained
- Cytohistopathology: N:C ratio > 0.7; nuclear pleomorphism; moderate to severe hyperchromasia
- High-grade urothelial carcinoma
REFERENCE
1. Galsky MD, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. J Clin Oncol. 2025;43(1):15-21. doi:10.1200/JCO.24.00340
Articles in this issue
Advertisement
Related to this article

The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.

UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5
